1. Kimyai-Asadi A, Harris JC, Nousari HC. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999;60(10):714-25.
2. MacMorran WS, Krahn LE. Adverse cutaneous reactions to psychotropic drugs. Psychosomatics 1997;38(5):413-22.
3. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356(9237):1255-9.
4. Babu KS, Belgi G. Management of cutaneous drug reactions. Curr Allergy Asthma Rep 2002;2(1):26-33.
5. Shear NH, Knowles SR, Sullivan JR, Shapiro L. Cutaneous reactions to drugs. In: Freedburg IM, Eisen AZ, Wolff K, et al, eds. Fitzpatrick’s dermatology in general medicine. 6th ed. New York, NY: McGraw-Hill; 2003:1330-7.
6. Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol 2003;3:278-99.
7. Chosidow OM, Stern RS, Wintroub BU. Cutaneous drug reactions. In: Kasper DL, Braunwald E, Fauci AS, et al, eds. Harrisons’s principles of internal medicine. 16th ed. New York, NY: McGraw-Hill; 2005:318-24.
8. Odom RB, James WD, Berger TG. Contact dermatitis and drug eruptions. In: Andrew’s diseases of the skin: clinical dermatology. 9th ed. Philadelphia, PA: W.B. Saunders Co.; 2000:95-145.
9. Rojeau JC, Stern RS. Medical progress: severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331(19):1272-85.
10. Breathnach SM. Adverse cutaneous reactions to drugs. Clin Med 2002;2(1):15-9.
11. du Vivier A, McKee PH, Stoughton RB. Drug and toxic eruptions of the skin. In: du Vivier A, McKee PH, Stoughton RB. Atlas of clinical dermatology. Philadelphia, PA: W.B. Saunders Co.; 1986:14.1-14.18.
12. Warnock JK, Morris DW. Adverse cutaneous reactions to mood stabilizers. Am J Clin Dermatol 2003;4(1):21-30.
13. Mann SC, Walker MM. Leukocytoclastic vasculitis secondary to trazodone treatment. J Am Acad Dermatol 1984;10(4):669-70.
14. Hearn R. Recognition and management of cutaneous photosensitivity. Practitioner 2005;249(1671):418-32.
15. Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention, and management. Drug Saf 2002;25(5):345-72.
16. Crowson AN, Brown TJ, Magro CM. Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions. Am J Clin Dermatol 2003;4(6):407-28.
17. Remmer HI. Successful treatment of lithium-induced acne. J Clin Psychiatry 1986;47(1):48.-
18. Warnock JK, Morris DW. Adverse cutaneous reactions to antidepressants. Am J Clin Dermatol 2002;3(5):329-39.
19. Warnock JK, Morris DW. Adverse cutaneous reactions to antipsychotics. Am J Clin Dermatol 2002;3(9):629-36.
20. Physicians desk reference. 61st ed. Montvale, NJ: Thomson PDR; 2007.
21. Atkin DH, Fitzpatrick RE. Laser treatment of imipramine-induced hyperpigmentation. J Am Acad Dermatol 2000;43(1 Pt 1):77-80.
22. Thompson TR, Lal S, Yassa R, Gerstein W. Resolution of chlorpromazine-induced pigmentation with haloperidol substitution. Acta Psychiatr Scand 1988;78(6):763-5.
23. Bloom D, Krishnan B, Thavundayil JX, Lal S. Resolution of chlorpromazine-induced cutaneous pigmentation following substitution with levomepromazine or other neuroleptics. Acta Psychiatr Scand 1993;87(3):223-4.
24. Mercke Y, Sheng H, Khan T, Lippmann S. Hair loss in psychopharmacology. Ann Clin Psychiatry 2000;12(1):35-42.
25. Warnock JK. Psychotropic medication and drug-related alopecia. Psychosomatics 1999;32(2):149-52.
26. Gupta AK, Knowles SR, Gupta MA, et al. Lithium therapy associated with hidradenitis suppurativa: case report and review of the dermatologic side effects of lithium. J Am Acad Dermatol 1995;32(2 part 2):382-6.
27. Osborne SF, Stafford L, Orr KD. Paroxetine-associated psoriasis. Am J Psychiatry 2002;59(12):2113.-
28. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999;33(10):1037-42.
